International Edition
Latest News
Health

Azacitidine Kills Leukemia Cells via RNA, Not DNA, Study Finds

"If DNA were the substrate, then decitabine should work better than azacitidine, but it is the opposite," said Chuan He, the John T. Wilson Distinguished Service Professor of Chemistry at the University of Chicago and senior author of…

Azacitidine Kills Leukemia Cells via RNA, Not DNA, Study Finds

“If DNA were the substrate, then decitabine should work better than azacitidine, but it is the opposite,” said Chuan He, the John T. Wilson Distinguished Service Professor of Chemistry at the University of Chicago and senior author of the study.

Researchers at the University of Chicago and UT Health San Antonio have discovered that azacitidine, a frontline treatment for high-risk myelodysplastic syndromes and acute myeloid leukemia, kills cancer cells primarily by targeting RNA rather than DNA during the critical first day of treatment. The findings, published in Molecular Cell, overturn two decades of classification that labeled the drug a DNA hypomethylating agent.

Azacitidine helps only a third to half of patients, and clinicians have lacked reliable biomarkers to predict response. The new data show that within eight hours of exposure, levels of the chemical tag 5-methylcytosine on chromatin-associated RNA plummet, while DNA methylation remains unchanged for at least 24 hours.

The drug traps NSUN2, the enzyme that installs those RNA tags, disabling DNA repair and shutting down growth genes rapidly — effects that decitabine, a sister drug restricted to DNA incorporation, fails to replicate in the same window.

Azacitidine Kills Leukemia Cells via RNA, Not DNA, Study Finds
Photo: biologicalsciences.uchicago.edu

The DNA-centric model left major gaps: gene-activity changes after treatment often did not match DNA demethylation, and some patients benefited without measurable DNA changes. Decitabine incorporates only into DNA, yet azacitidine sees wider clinical use despite the assumption that both act through the same pathway.

He’s laboratory previously showed that leukemia cells depend on methyl tags on nuclear RNA to keep growth genes active. The current study, led by first author Boyang Gao, used high-precision mass spectrometry and a biochemical technique that captures proteins cross-linked to nucleic acids to track the drug’s earliest actions. NSUN2 binding peaked at eight hours, coinciding with the collapse of RNA methylation and the onset of gene silencing.

Direct comparison with decitabine confirmed the divergence. Within 24 hours, azacitidine shut down gene activity, crippled DNA repair, and triggered cell death. Decitabine had almost no effect on survival in that period. Genetic depletion of NSUN2 mimicked azacitidine’s rapid toxicity, while depleting DNMT1, the main DNA methyltransferase, produced the opposite effect.

“Both are used as hypomethylating agents to treat leukemia, but azacitidine is used in the majority of patients and decitabine in a smaller portion,” He said. “They clearly have different clinical toxicity, yet people somehow think they work the same way, but we know most of the azacitidine goes into RNA.”

Leukemia cells harboring mutations in TET2 or IKZF1 proved especially sensitive to RNA methylation loss, suggesting potential predictive markers. The rapid cell death also explains the strong synergy with venetoclax, now a standard combination for older adults with AML.

Chuan He, a chemical biologist born in China, earned his Ph.D. at the Massachusetts Institute of Technology and joined the University of Chicago faculty in 2002. His laboratory discovered the first RNA demethylase that reverses m6A methylation in 2011, revealing that this abundant RNA mark regulates gene expression.

He later invented TAB-seq, a method to map 5-hydroxymethylcytosine in DNA at base resolution. For these contributions, he received the 2023 Wolf Prize in Chemistry and was elected to the National Academy of Sciences in 2026.

“Our study suggests that if we can inhibit NSUN2 specifically, we may be able to avoid resistance from inhibiting too many enzymes,” He said. “Our plan is to develop NSUN2 inhibitors that we can test in further studies.”

About the author: Health Desk

Health Desk at Archynewsy.